The Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma: A Systematic Review of the Literature.

Autor:	Khorochkov A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Prieto J; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Singh KB; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Nnadozie MC; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Shrestha N; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Dominic JL; General Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, USA.; General Surgery and Orthopaedic Surgery, Cornerstone Regional Hospital/South Texas Health System, Edinburg, USA.; General Surgery, LaSante Health Center, Brooklyn, USA., Abdal M; Emergency Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Abe RAM; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Masroor A; Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; Psychiatry, Psychiatric Care Associates, Englewood, USA.; Medicine, Khyber Medical College, Peshawar, PAK., Mohammed L; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Sep 27; Vol. 13 (9), pp. e18334. Date of Electronic Publication: 2021 Sep 27 (Print Publication: 2021).
DOI:	10.7759/cureus.18334
Abstrakt:	Multiple myeloma (MM) is an indolent B-cell malignancy, where treatment is aimed at preventing organ dysfunction from light chain accumulation (slowing disease progression) and inducing remission. Allogeneic stem cell transplant (allo-SCT), through graft versus myeloma (GVM) effects, has the potential to induce remission to a potentially curative-like state. In this systematic review, we aimed to understand this relationship to the risks and severity of disease in categorized patients and gain an updated comprehension of the future of allo-SCT in MM treatment. We conducted this review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and searched the PubMed database to obtain the specified literature with both the use of keywords and Medical Subject Headings (MeSH). A total of 16 relevant articles were included for discussion after the quality appraisal was completed, as appropriate, by either the Cochrane tool or Newcastle-Ottawa checklist. Our review concludes that while allo-SCT may benefit high-risk patients, successful procedures may incorporate a tandem autologous hematopoietic stem cell transplant approach in combination with novel pharmacologic contributions for which there is an observed synergy in the modulation of the immunologic microenvironment. Furthermore, tailored patient selection by evaluating pre-transplant factors including high-risk cytogenetics, age, and pre-salvage International Staging System (ISS) can predict post-transplantation success including non-relapse mortality. Successive research should continue to revise and update treatment options as the evolving therapeutic drug regimens may change over the course of indolent disease. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Khorochkov et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu